Perrigo’s Nasonex 24HR Allergy Receives the US FDA’s Approval for Nasal Allergy Spray
Shots:
- The US FDA has approved Nasonex 24HR Allergy (mometasone furoate monohydrate) for over-the-counter use to prevent hay fever & allergy symptoms including allergic rhinitis, nasal congestion associated with seasonal allergic rhinitis, nasal polyps, and the prophylaxis of seasonal allergic rhinitis
- Nasonex (Rx-to-OTC switch) marks the first OTC formulation & is expected to be available at the end of 2022 with full prescription strength. Additionally, each nasal spray delivers 50mcg of mometasone furoate monohydrate delivering
- The company focuses on providing affordable self-care products to the patients with good quality strengthening internal innovation, R&D & regulatory capabilities
Ref: PRNewswire | Image: Wikipedia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
